MSM Protein Technologies Secures Second Pre-Clinical Debiopharm Milestone


We are pleased to announce that MSM has satisfied the second pre-clinical milestone in its collaboration with Debiopharm International headquartered in Lausanne, Switzerland. Debiopharm has determined that antibodies generated by MSM have demonstrated the required in vivo efficacy as stipulated in our collaboration agreement and the project has moved into the next phase of development.

About MSM Protein Technologies

MSM Protein Technologies is a closely held drug discovery company that specializes in discovering antibodies targeting complex cell surface receptors such as G Protein- Coupled Receptors (GPCRs). Using proprietary technologies originating at the Dana Farber Institute and developed within MSM, the company is able to overexpress the cell surface proteins in their native conformation, maximizing the possibility of discovering functional antibodies.

For more information: 781-321-3322